Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | BIO.B | PSO |
|---|---|---|
| Price | $365.08 | $16.24 |
| Change today | ▲ 0.00% | ▲ 0.74% |
| Market cap | $9.76B | $9.76B |
| Return, 3 months | +23.1% | -3.0% |
| Return, year to date | +17.5% | +18.6% |
| Return, 1 year | +28.2% | +17.2% |
| P/E (TTM) | 44.5 | 24.6 |
| P/B | 1.4 | 2.2 |
| P/E percentile vs own 5y | – | – |
| Dividend yield | – | 2.11% |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | – | – |
| Analyst buy share | – | – |
| RSI (14) | 97 | 55 |
| 30-day volatility | 0.0% | 18.0% |
| Max drawdown, 1 year | -20.4% | -19.5% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
